Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (13340)	3/8/2004 12:12:48 PM
From: twentyfirstcenturyfox	Respond to of 14101

Thanks Wolf, if I may. Summary: 1. Provalis was a poor deal and the wrong company for DMX - altho' that does not mean that Provalis is not a good company - I am a shareholder. 2. DMX lost cred. as a consequence of poor interpersonal skills by our Prez. (who, incidentally, on announcing the deal, implied that it was "better than going with a major"). 3. Now, we get the benefit of In2Focus' cred, but it will cost us: - whathasbeendiscussedadnaseum... - margin points... - not to mention time - which is - too tight to mention. As they say in Kerry: <it is well within the bounds of possibility, that I am not totally overwhelmed with this announcement>. Fox.

To: Montana Wildhack who wrote (13340)	3/8/2004 12:30:47 PM
From: toccodolce	Read Replies (1) \| Respond to of 14101

Found this at Yahoo Biotech news biz.yahoo.com Reuters Dimethaid shares jump on U.K. sales-force boost Monday March 8, 12:03 pm ET TORONTO, March 8 (Reuters) - Shares of Dimethaid Research Inc. (Toronto:DMX.TO - News) rose more than 9 percent on Monday after it said the sales force that markets its flagship drug for arthritic pain in the United Kingdom will more than double. ADVERTISEMENT Dimethaid, based in Markham, Ontario, said U.K. sales firm In2Focus will expand its sales force to 50 from 20 for Pennsaid, a lotion used for relief from arthritis. The 50-strong sales force will market Pennsaid and another drug made by a major international pharmaceutical company that does not compete with Pennsaid. "We're effectively increasing our sales efforts 150 percent," Jodi Peake, a spokeswoman for Dimethaid, said. "The financial impact of this deal will be very minimal, nonmaterial to us." Dimethaid shares, down 44 percent in the past year, were up 10 Canadian cents at C$1.27 on the Toronto stock exchange. Pennsaid is sold in Canada, the United Kingdom, Italy and several countries in the Caribbean. It will be launched in Greece and Portugal later this year. The company has not provided any forecasts for sales for the fiscal year ending May 2004. "We're breaking new ground here. At this point we need to position ourselves to provide guidance," Peake said. Pennsaid is also awaiting a final approval decision from the U.S. Food and Drug Administration (News - Websites) . The company is seeking distribution deals in Iceland and Finland, where Pennsaid has received regulatory approval. Dimethaid says Pennsaid delivers the active drug through the skin and is not associated with an increased risk of stomach and intestinal problems, common symptoms with oral medications for arthritis pain. The most commonly reported reaction to Pennsaid is dry skin at the area of application. Related News Stories · In2Focus steps up U.K. Pennsaid(R) promotion - Canada NewsWire (8:01 am) · Dimethaid shares up on anti-arthritic lotion deal - Reuters (Mon Feb 23) · Pennsaid(R) to be distributed in Greece - Canada NewsWire (Mon Feb 23) · Dimethaid and Solvay team up to sell Pennsaid(R) in Canada - Canada NewsWire (Wed Feb 11) More... -------------------------------------------------------------------------------- Copyright © 2004 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Ad Feedback Copyright © 2004 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.